Innovating Works

STIFTUNG LEIBNIZINSTITUT FUR IMMUNTHERAP...

Desconocido
CAR T-REX: CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment STIFTUNG LEIBNIZINSTITUT FUR IMMUNTHERAPIE participó en un HORIZON EUROPE: HORIZON-EIC-2022-PATHFINDEROPEN-01 Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gain...
2022-12-16 - 2027-03-31 | Financiado
T-FITNESS: FINE-TUNING T CELL NETWORKS OF EXHAUSTION BY SYNTHETIC SENSORS STIFTUNG LEIBNIZINSTITUT FUR IMMUNTHERAPIE tramitó un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 Cell and gene therapies offer a massive paradigm shift from current treatment options and hold the potential to cure previously untreatable...
2022-07-08 - 2026-08-31 | Financiado
INCITE: Immune Niches for Cancer ImmunoTherapy Enhancement STIFTUNG LEIBNIZINSTITUT FUR IMMUNTHERAPIE participó en un H2020: H2020-FETOPEN-2018-2020 Cancer is rapidly becoming the most frequent cause of morbidity and mortality in the EU, accounting for a quarter of all deaths in EU. Witho...
2020-12-21 - 2025-04-30 | Financiado
PAVE: A nanovaccine Approach for the treatment of Pancreatic Cancer STIFTUNG LEIBNIZINSTITUT FUR IMMUNTHERAPIE participó en un H2020: H2020-MSCA-ITN-2019 A Nanovaccine Approach For The Treatment of Pancreatic Cancer By Multicomponent Immuno-Modulation: Pancreatic ductal adenocarcinoma (PDAC) i...
2019-09-12 - 2024-03-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.